CDAK
CODIAK BIOSCIENCES INC (CDAK)
$0.80647.52%▲
Market is closedMarket is closed – opens on 8 PM, 06 Feb 2023
– opens on 8 PM, 06 Feb 2023
Key Stats
$0.75
Day's Range
$0.936
$0.3
52-Week Range
$7.15
| Returns % | |
| 1 month return | 49.33% |
| 3 month return | 1.01% |
| 1 year return | 83.9% |
| 5 year return | 93.35% |
Analyst Recommendation
based on 10 analysts ratings
Buy
80%
Buy
20%
Hold
0%
Sell
Based on 10 Wall street analysts offering stock ratings for CODIAK BIOSCIENCES INC(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 619.25%Current
$0.81
Target
$5.8
Recommendation Trend
Based on 10 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 8 | 3 | 8 |
| Hold | 2 | 0 | 2 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Highlights
| Market Capitalization | 29.3M |
| Book Value | $1.06 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.56 |
| Wall Street Target Price | 5.8 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.55 |
| Enterprise Value | 30.9M |
| Enterprise Value/Revenue | 0.92 |
| Enterprise Value/Ebitda | -3.28 |
Technicals
| Beta | 3.46 |
| 50 Day MA | 0.58 |
| 200 Day MA | 1.73 |
Institutional Holdings
FMR Inc
12.17%
Flagship Ventures Management, Inc.
9.61%
LAURION CAPITAL MANAGEMENT LP
5.47%
Armistice Capital, LLC
2.72%
Alaska Permanent Fund Corp
2.66%
University Of Texas Investment Mgmt Co
2.3%
Company Information
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of diseases, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
| Organization | CODIAK BIOSCIENCES INC |
| Employees | 102 |
| CEO | Dr. Douglas Edward Williams Ph.D. |
| Industry | Commercial Services |
Discover more
Frequently Asked Questions
What is CODIAK BIOSCIENCES INC share price today?
Can Indians buy CODIAK BIOSCIENCES INC shares?
How can I buy CODIAK BIOSCIENCES INC shares from India?
Can Fractional shares of CODIAK BIOSCIENCES INC be purchased?
What are the documents required to start investing in CODIAK BIOSCIENCES INC stocks?
What are today’s High and Low prices of CODIAK BIOSCIENCES INC?
What are today’s traded volumes of CODIAK BIOSCIENCES INC?
What is today’s market capitalisation of CODIAK BIOSCIENCES INC?
What is the 52 Week High and Low Range of CODIAK BIOSCIENCES INC?
How much percentage CODIAK BIOSCIENCES INC is down from its 52 Week High?
How much percentage CODIAK BIOSCIENCES INC is up from its 52 Week low?
What are the historical returns of CODIAK BIOSCIENCES INC?
Who is the Chief Executive Officer (CEO) of CODIAK BIOSCIENCES INC?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*